Prosecution Insights
Last updated: July 17, 2026
Application No. 17/798,904

HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR

Final Rejection §112
Filed
Aug 11, 2022
Priority
Feb 24, 2020 — provisional 62/980,700 +2 more
Examiner
PECKHAM, RICHARD GRANT
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Newave Pharmaceutical Inc.
OA Round
4 (Final)
67%
Grant Probability
Favorable
5-6
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allowance Rate
86 granted / 128 resolved
+7.2% vs TC avg
Strong +36% interview lift
Without
With
+35.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
54 currently pending
Career history
179
Total Applications
across all art units

Statute-Specific Performance

§101
2.4%
-37.6% vs TC avg
§103
30.9%
-9.1% vs TC avg
§102
6.1%
-33.9% vs TC avg
§112
13.6%
-26.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 128 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Response to Amendment The amendment filed 4/03/2026 has been entered. Newly amended Claims 1, 19, 26, 41, 51-65 are pending in the application. Claims 54-57 and 60-61 remain withdrawn. Claims 1, 19, 26, 41, 51-53, 58-59, and 62-65 are examined on the merits herein. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied and constitute the complete set presently being applied to the instant application. Response to Applicant’s Arguments Applicant argues that the Chen declaration filed 4/03/2026 is sufficient to disqualify Chen as prior art under 102(a)(1). Chen, the sole inventor named in the instant application, testifies that he is the sole inventor of the extant seven compounds of amended Claim 1 and that Yan Lou, a coinventor listed in the Chen reference, did not invent the claimed compounds. The affidavit is considered and sufficient to withdraw the rejection over 35 USC 103 over Chen. See MPEP 717.01(a). Therefore, the prior art rejection over Chen is withdrawn and the double patenting rejections wherein Chen is cited as a secondary reference are also withdrawn. See MPEP 804 (II)(B)(3). Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 58-59 and 62-65 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention. Claim 58 recites the limitations “the…carrier”, “the surfactant”, and “the antioxidant”. There is insufficient antecedent basis for this limitation in the claim. Claim 1 upon which Claim 58 depends does not recite the terms carrier, surfactant, or antioxidant following the amendments filed 4/03/2026. Claims 59 and 62-65 are rejected by virtue of dependency. Conclusion Claims 1, 19, 26, 41, and 51-53 are allowable. Claims 58-59 and 62-65 are rejected. Applicant’s amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Inquiries Any inquiry concerning this communication or earlier communications from the examiner should be directed to Richard G. Peckham whose telephone number is (703)756-4621. The examiner can normally be reached 7:30am - 4:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached on (571) 270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RICHARD GRANT PECKHAM/Examiner, Art Unit 1627 /Kortney L. Klinkel/Supervisory Patent Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Show 2 earlier events
Apr 14, 2025
Response Filed
Jun 11, 2025
Final Rejection mailed — §112
Nov 10, 2025
Request for Continued Examination
Nov 12, 2025
Response after Non-Final Action
Dec 23, 2025
Non-Final Rejection mailed — §112
Apr 03, 2026
Response after Non-Final Action
Apr 03, 2026
Response Filed
May 11, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12678451
CANNABINOID AND OMEGA FATTY ACID COMPOSITIONS AND METHODS OF USING
3y 5m to grant Granted Jul 14, 2026
Patent 12673022
DRUG DELIVERY SYSTEM USING SOLUTION
5y 1m to grant Granted Jul 07, 2026
Patent 12648936
ISOTHIAZOLIDINE 1,1-DIOXIDE AND 1,4-BUTAN SULTONE CONTAINING RAPAMYCIN DERIVATIVES AND USES THEREOF
4y 8m to grant Granted Jun 09, 2026
Patent 12642794
DOSE REGIMENS FOR USE OF LY3154207 IN THE TREATMENT OF DOPAMINERGIC CNS DISORDERS
4y 11m to grant Granted Jun 02, 2026
Patent 12636290
BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD
4y 11m to grant Granted May 26, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
67%
Grant Probability
99%
With Interview (+35.9%)
3y 3m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 128 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month